36 research outputs found
The Public Repository of Xenografts enables discovery and randomized phase II-like trials in mice
More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX) in mice could efficiently define therapeutic activity across heterogeneous tumors. To address this hypothesis, we established a large, publicly available repository of well-characterized leukemia and lymphoma PDXs that undergo orthotopic engraftment, called the Public Repository of Xenografts (PRoXe). PRoXe includes all de-identified information relevant to the primary specimens and the PDXs derived from them. Using this repository, we demonstrate that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease
Recommended from our members
Viewpoint: The black-tailed prairie dog—headed for extinction?
The black-tailed prairie dog (Cynomys ludovicianus) is 1 of 5 western prairie dog species, and the only species found on the Great Plains. Some authorities believe the black-tailed prairie dog may have been the most numerous of mammalian herbivores found on the plains with some estimates placing their historic numbers as high as 5 billion. Due to a combination of factors including habitat destruction, hunting, plague, and poisoning programs, the black-tailed prairie dog may now be threatened with extinction across its entire range. In this paper, a tentative prairie dog conservation strategy consisting of core reserves, buffer areas, and corridors is proposed.The Journal of Range Management archives are made available by the Society for Range Management and the University of Arizona Libraries. Contact [email protected] for further information.Migrated from OJS platform August 202
Characterization of 14 polymorphic microsatellite markers for the black-tailed prairie dog (Cynomys ludovicianus)
Life in silico - simulation of complex systems by enzymatic computation
SIGLEAvailable from TIB Hannover: RA 2999(00-147) / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische InformationsbibliothekDEGerman
Supplementary Material for: The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1
<p><b><i>Background/Aims:</i></b> The tumor suppressor p53 is depleted
in many tumor cells by the E3 ubiquitin ligase mouse double minute 2
homolog (MDM2) through MDM2/p53 interaction. A novel target for
inhibiting p53 degradation and for causing reexpression of p53<sup>wild type</sup>
is inhibition of MDM2. The small molecule NVP-CGM097 is a novel MDM2
inhibitor. We investigated MDM2 inhibition as a target in neuroendocrine
tumor cells in vitro. <b><i>Methods:</i></b> Human neuroendocrine tumor
cell lines from the pancreas (BON1), lung (NCI-H727), and midgut (GOT1)
were incubated with the MDM2 inhibitor NVP-CGM097 (Novartis) at
concentrations from 4 to 2,500 nM. <b><i>Results:</i></b> While p53<sup>wild type</sup> GOT1 cells were sensitive to NVP-CGM097, p53<sup>mutated</sup> BON1 and p53<sup>mutated</sup> NCI-H727 cells were resistant to NVP-CGM097. Incubation of GOT1 cells with NVP-CGM097 at 100, 500, and 2,500 nM for 96 h caused a significant decline in cell viability to 84.9 ± 9.2% (<i>p</i> < 0.05), 77.4 ± 6.6% (<i>p</i> < 0.01), and 47.7 ± 9.2% (<i>p</i>
< 0.01). In a Western blot analysis of GOT1 cells, NVP-CGM097 caused
a dose-dependent increase in the expression of p53 and p21 tumor
suppressor proteins and a decrease in phospho-Rb and E2F1. Experiments
of co-incubation of NVP-CGM097 with 5-fluorouracil, temozolomide, or
everolimus each showed additive antiproliferative effects in GOT1 cells.
NVP-CGM097 and 5-fluorouracil increased p53 and p21 expression in an
additive manner. <b><i>Conclusions:</i></b> MDM2 inhibition seems a promising novel therapeutic target in neuroendocrine tumors harboring p53<sup>wild type</sup>. Further investigations should examine the potential role of MDM2 inhibitors in neuroendocrine tumor treatment.</p
Inhibition of wild-type p53-expressing AML by the novel small molecule HDM2 inhibitor CGM097
The tumor suppressor p53 is a key regulator of apoptosis and functions upstream in the apoptotic cascade by both indirectly and directly regulating Bcl-2 family proteins. In cells expressing wild-type (WT) p53, the HDM2 protein binds to p53 and blocks its activity. Inhibition of HDM2:p53 interaction activates p53 and causes apoptosis or cell-cycle arrest. Here, we investigated the ability of the novel HDM2 inhibitor CGM097 to potently and selectively kill WT p53-expressing AML cells. The antileukemic effects of CGM097 were studied using cellbased proliferation assays (human AML cell lines, primary AML patient cells, and normal bone marrow samples), apoptosis, and cell-cycle assays, ELISA, immunoblotting, and an AML patient-derived in vivo mouse model. CGM097 potently and selectively inhibited the proliferation of human AML cell lines and the majority of primary AML cells expressing WT p53, but not mutant p53, in a target-specific manner. Several patient samples that harbored mutant p53 were comparatively unresponsive to CGM097. Synergy was observed when CGM097 was combined with FLT3 inhibition against oncogenic FLT3-expressing cells cultured both in the absence as well as the presence of cytoprotective stromal-secreted cytokines, as well as when combined with MEK inhibition in cells with activated MAPK signaling. Finally, CGM097 was effective in reducing leukemia burden in vivo. These data suggest that CGM097 is a promising treatment for AML characterized as harboring WT p53 as a single agent, as well as in combination with other therapies targeting oncogene-activated pathways that drive AML